Advertisements

Oftan Akvakol

Quick links to important sections

Oftan Akvakol

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Oftan Akvakol

What is Oftan Akvakol?

Oftan Akvakol is an antimicrobial medication used in the field of ophthalmology. It is formulated as eye drops and contains the active substance chloramphenicol, which is a broad-spectrum antibiotic.

Mechanism of Action

The active ingredient, chloramphenicol, works by inhibiting bacterial protein synthesis. It prevents the growth and multiplication of bacteria by binding to the bacterial ribosome, which interferes with the formation of essential proteins. This action helps the body's natural immune system to manage and resolve the infection.

Therapeutic Use

This medication is primarily used for the treatment of superficial eye infections. Its broad-spectrum nature means it is effective against a wide variety of both Gram-positive and Gram-negative bacteria that commonly affect the external structures of the eye.

Typical conditions for which this medication may be utilized include:

  • Bacterial conjunctivitis: Infection of the membrane covering the white part of the eye and the inner surface of the eyelids.
  • Keratitis: Inflammation or infection of the cornea.
  • Blepharitis: Inflammation of the eyelid margins caused by bacterial activity.

Characteristics

Oftan Akvakol is designed for local application to ensure that the concentration of the antibiotic is highest at the site of the infection while minimizing systemic absorption. The formulation is intended to provide consistent contact with the ocular surface to support the resolution of bacterial symptoms.

Regulatory References

  1. MedlinePlus: Chloramphenicol (NIH/NLM)
  2. Chloramphenicol Mechanism of Action (NIH/NCBI Bookshelf)
Advertisements

What side effects are possible with Oftan Akvakol?

Possible side effects associated with Oftan Akvakol are formally classified in regulatory documents based on the affected physiological systems and frequency. The most commonly reported events are local and transient, falling under Eye disorders. These typically include a transient stinging or burning sensation and mild irritation immediately following application. Localized hypersensitivity reactions, such as dermatitis or itching, are also officially documented.

A primary safety concern documented in official prescribing information is the potential for systemic absorption of the active ingredient, Chloramphenicol, from the ocular surface. This absorption carries a rare but serious risk of adverse reactions affecting the Blood and Lymphatic System. The most clinically significant of these, although very rarely reported after topical use, is aplastic anaemia and other forms of bone marrow depression. Severe immune responses, including angioedema and anaphylaxis, are also listed as possible serious adverse reactions.

The drug's safety profile includes specific constraints regarding duration and population. Prolonged or chronic use is explicitly discouraged by regulators to limit the potential for systemic toxicity and the development of resistance. Caution is specifically noted for use in newborn infants/neonates due to their reduced capacity for systemic elimination, and use during pregnancy and lactation is generally not recommended due to established safety constraints.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Oftan Akvakol (Chloramphenicol Ophthalmic Solution) addresses both local exposure and potential systemic overdose scenarios.

The product is formulated to be unlikely to cause systemic toxicity following typical over-application due to the low concentration of the active ingredient. However, local signs of over-exposure or undesired eye contact are documented, which may include eye irritation, pain, swelling, excessive tearing (lacrimation), and photophobia.


Required Actions and Regulatory Mandates

Action Type Official Guidance
Local Exposure Irrigate the affected eye with water. Symptomatic treatment should be given. An ophthalmological examination should be considered if local symptoms persist after irrigation.
Urgent Medical Help If ingestion or overdose is suspected, it is mandated to contact a healthcare professional, hospital emergency department, or regional poison control center immediately.

Population-Specific Risk: Regulatory information notes a severe systemic hazard associated with Chloramphenicol: the potential for the life-threatening Gray syndrome in premature and newborn infants if systemic exposure occurs. No specific antidote is documented as required for overdosage with the eye drops.

Advertisements

Therapeutic Uses of Oftan Akvakol

What Oftan Akvakol treats: Main Uses and Benefits

Oftan Akvakol eye drops contain the antibiotic chloramphenicol and are commonly used to help with superficial eye infections, as a part of symptomatic management. The active ingredient in these eye drops is generally considered relevant for easing symptoms that interfere with daily functioning by targeting the bacteria responsible for the infection.

The drug is applied in addressing symptom clusters that may become intense or disruptive, such as those associated with bacterial conditions involving inflammatory or irritative processes, including conditions where symptoms relate to organ-specific functional stress like in the conjunctiva or cornea. Its activity is considered relevant in conditions where symptoms may intensify temporarily due to common bacterial agents.

This medication is applied in addressing symptom clusters that may become intense or disruptive, such as noticeable redness, irritation, or discharge in the eye. It provides supportive relief when symptoms of increased neurological or muscular activity are caused by bacterial conditions presenting with systemic or localized discomfort. The overarching patient benefit is that it contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability during episodes of heightened symptoms.


Quick Fact: Relief for Irritation and Redness

Regulatory References

  1. NIH DailyMed Prescribing Information for Chloramphenicol Ophthalmic Ointment
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Oftan Akvakol?

The eligibility for Oftan Akvakol is defined by formal regulatory documentation, outlining specific populations who are permitted, restricted, or prohibited from using the medicine.

Populations for Whom Use is Contraindicated

This medicine must not be used by patients with a known personal or family history of blood dyscrasias, including aplastic anaemia. Use is also strictly contraindicated for individuals with a history of myelosuppression (bone marrow depression) following previous exposure to chloramphenicol, or those with known hypersensitivity to the active substance.

Age and Physiological Status

Category Eligibility Status
Adults and Children Generally allowed for use in adults and children aged 2 years and over.
Infants (0 to 2 years) Use is permitted, but requires a doctor’s prescription and careful medical oversight.
Pregnancy and Lactation Not Recommended. Safety has not been established, and the drug may be absorbed systemically and cross the placenta or appear in breast milk.

Specific Restrictions

Patients who wear contact lenses must remove them for the entire course of treatment. The label also requires individuals with a history of certain eye conditions, such as glaucoma or recent eye surgery, to seek medical advice before beginning therapy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The active ingredient in Oftan Akvakol (chloramphenicol) has the potential to interact with a specific list of other medicines, primarily by affecting their metabolism in the body. Although Oftan Akvakol is an eye drop solution, systemic absorption can still occur, making these interactions clinically relevant.

Potential Drug Interactions

Certain combinations are usually not recommended due to the risk of increased concentration and side effects of the interacting drug. These include co-administration with:

  • Anticonvulsants (Hydantoins): Such as Phenytoin and Fosphenytoin. Chloramphenicol is known to inhibit the liver enzymes (Cytochrome P450) responsible for metabolizing these drugs, which can lead to elevated blood concentrations of the anticonvulsant and signs of toxicity.
  • Immunosuppressants: Such as Tacrolimus and Cyclosporine, where increased drug levels may be a risk.
  • Antifungals and Anti-Tuberculosis agents: Including Voriconazole and Rifampin.
  • Vaccines: The use of Oftan Akvakol is generally not recommended in combination with Cholera Vaccine, Live.

Other medicines, including Dicumarol (an oral anticoagulant) and Chlorpropamide, may have an increased risk of certain side effects when used with Oftan Akvakol. If concurrent use of any listed interacting drug is necessary, the prescribing healthcare professional may need to change the dosage or frequency of one or both medicines to maintain safety and efficacy.

Advertisements

Mechanism of Action

Oftan Akvakol contains the compound chloramphenicol, a broad-spectrum bacteriostatic agent. This compound targets the bacterial 50S ribosomal subunit.

The interaction type is a direct inhibitor of the peptidyl transferase enzyme within the 50S subunit. Specifically, chloramphenicol binds reversibly to the 50S subunit at a site proximal to the binding location of the acceptor aminoacyl-transfer RNA (tRNA) end. This binding action blocks the essential peptidyl transferase step of protein synthesis, preventing the formation of peptide bonds between amino acid residues.

This molecular interaction results in the inhibition of elongation of the nascent polypeptide chain, thereby suppressing the overall bacterial protein synthesis pathway. The intracellular consequence is a cessation of new protein production required for cellular growth and replication. At a system level, this leads to a reduction in the overall bacterial population, which modulates the physiological consequences of infection.

Advertisements

Dosage and Administration Information

The administration of Oftan Akvakol (Chloramphenicol Ophthalmic Solution) is strictly confined to topical ocular use, involving the direct instillation of drops into the affected eye(s). The standard dose for adults and the elderly involves applying one to two drops per administration.

Dosing Frequency and Duration

The official regimen begins with a high-frequency schedule, typically requiring application every two to three hours during waking hours only. Following the initial period (e.g., the first 48 hours) or as the eye condition improves, the frequency is generally reduced. The course of treatment is mandated to continue for at least 48 hours after the eye appears normal, but the total duration is usually limited to a maximum of 5 days. If a dose is missed, it should be administered immediately unless the time for the next scheduled dose is near, in which case the missed dose is skipped.

Procedural and Population Constraints

Procedural instructions require that soft contact lenses be removed for the entire duration of the treatment, as the preservative in the solution can be absorbed by the lenses. To maintain the sterility of the solution, the dropper tip must not contact the eye or any other surface. While the standard adult regimen is used for the elderly, specific caution is necessary for newborn infants. This is due to the potential for reduced systemic elimination of the medicine resulting from immature metabolic pathways, which may necessitate a dosage adjustment.

Advertisements

Recent Clinical Evidence

Oftan Akvakol: Recent Clinical Evidence

Evidence for Use in Acute Bacterial Conjunctivitis

Research for this compound has primarily focused on the context of acute bacterial conjunctivitis, a common eye infection. Researchers have conducted Randomized Controlled Trials (RCTs), where the eye drops were compared against a non-antibiotic placebo and other active compounds used in eye research. Data from these trials were combined and synthesized in Systematic Reviews and Meta-analyses (which combine results from multiple studies) to explore symptom patterns. Studies monitored several key outcomes related to physical discomfort and the underlying infection, including measuring Clinical Remission and Microbiological Remission (the clearance of the bacteria).

Research highlights changes measured during the study period: findings indicate that differences in resolution rates between the studied compound and the placebo were often observed to converge by the later stages of the infection (around Day 7 to Day 10). The difference in measured outcomes compared to the natural course of the infection alone was marginal in later stages.


Research Scope, Study Duration, and Uncertainties

Beyond acute conjunctivitis, the general application has also been evaluated in the broader context of superficial, external ocular infections caused by susceptible bacteria, supported by older controlled trials and broad regulatory reviews. Randomized Controlled Trials have included both adults and the pediatric population. The research focused on organisms known to be susceptible to the compound. Certain types of bacteria were not observed in studies to be impacted by the compound.

Follow-up durations were typically short, usually 7 to 10 days, to match the acute nature of the infection. Long-term effects are not fully established, and evidence is limited regarding the durability of the response. The primary research limitation is that the target condition is frequently self-limiting, which limits the insight available regarding functional outcomes compared to supportive care alone.

Key Studies & References

  1. Chloramphenicol eye drops containing borax and boric acid buffers: review of the use in children under 2 years - Public Assessment Report (MHRA)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Oftan Akvakol (FAQ)

Q: How quickly does Oftan Akvakol start to work?

Clinical experience described in patient information indicates that improvement in symptoms is typically observed within two days of starting to use the medicine. The official guidance for patients states that lack of improvement should be discussed with a healthcare professional.

Q: What is the duration of effect of a single use of Oftan Akvakol?

The required frequency of application reflects the expected duration of the medicine’s activity in the eye. Official dosing schedules often direct application every two to three hours during waking hours, which is consistent with the drug’s intended therapeutic presence in the eye.

Q: Can I use Oftan Akvakol if I wear contact lenses?

Official regulatory documents state that all contact lenses, including both soft and hard lenses, should typically be removed for the entire duration of the treatment. This is because the preservative in the solution can be absorbed by soft contact lenses.

Q: What kind of specialist usually prescribes Oftan Akvakol?

As a prescription-only medicine, it is typically prescribed by a qualified healthcare professional. This may include a general practitioner, an ophthalmologist, or, depending on local regulations, a prescribing optometrist.

Q: Are eye pain or irritation common side effects of Oftan Akvakol?

Mild irritation and a transient stinging or burning sensation immediately following application are commonly reported in official safety documents. Less frequent adverse effects listed in documentation may include eye pain.

Q: Why is Oftan Akvakol sometimes prescribed instead of an oral medication?

Oftan Akvakol is specifically formulated as an ophthalmic solution for topical use, meaning it is applied directly to the affected eye. This route of administration is indicated for local eye infections and helps to limit the systemic absorption of the active compound into the rest of the body.

Q: Does Oftan Akvakol help with long-term eye health?

The medicine is indicated only for the short-term treatment of acute bacterial eye infections. Regulatory documents explicitly discourage prolonged or chronic use.

Q: Why do some people need to use Oftan Akvakol for an extended period?

Official regulatory documents specify that the total treatment duration is typically limited to a maximum of 5 days, according to product information. Prolonged or chronic use is actively discouraged to limit the potential for systemic toxicity and the development of antibiotic resistance.

Q: Are headaches a possible side effect of Oftan Akvakol?

Headache is listed in official documentation among the possible nervous system adverse reactions associated with the active ingredient.

Q: Is it possible for Oftan Akvakol to interact with herbal supplements?

Official guidance notes that there is currently insufficient data available on the safety of using herbal supplements or complementary medicines with the active ingredient. Regulatory patient information emphasizes the importance of informing a healthcare professional of all products being used.

Q: Is there a risk of developing a tolerance to Oftan Akvakol over time?

Official safety statements relating to the antibiotic component discourage prolonged or chronic use. This constraint is in place to limit the potential for the development of antibiotic resistance in bacteria over time.

Q: Does Oftan Akvakol have any known systemic effects on the body?

Systemic absorption from the eye can occur, which means the medicine enters the bloodstream. This carries a rare but serious risk of adverse reactions affecting the Blood and Lymphatic System, such as aplastic anaemia and bone marrow depression.

Q: Are there special storage requirements for Oftan Akvakol?

Oftan Akvakol has specific storage requirements detailed in official instructions. It is typically mandated to be stored refrigerated, protected from light, and must not be frozen to maintain its stability and effectiveness.

Q: Can Oftan Akvakol be used to prevent an eye condition?

The medicine is indicated for the treatment of existing ocular bacterial infections. Official patient information notes that it should not be used for the purpose of preventing infections.

Q: What are the common reasons Oftan Akvakol might not work for someone?

The drug is effective only against bacteria that are susceptible to the compound. Reasons for treatment failure may include the infection being caused by an organism that is not susceptible, or the bacteria having developed resistance to the antibiotic.

Q: What is the maximum amount of time Oftan Akvakol is typically used?

The total duration of treatment is usually limited to a maximum of 5 days, according to official instructions. The course is mandated to continue for at least 48 hours after the eye appears normal.

Q: Is Oftan Akvakol indicated for use after eye surgery?

Official documentation requires individuals with a history of recent eye surgery to seek medical advice before beginning therapy. This is because the medicine may affect corneal wound healing.

Q: Does the time of day matter when using Oftan Akvakol?

The official regimen specifies that the medicine should be applied during waking hours only. This schedule is designed to maintain the required concentration of the medicine during the active phase of the infection.

Q: Is Oftan Akvakol known to cause dry mouth?

Dry mouth is listed in official documentation among the possible gastrointestinal adverse reactions associated with the active ingredient.

Q: What happens if Oftan Akvakol gets into the mouth or nose?

Official guidance in the patient information leaflet describes that if the medicine is accidentally swallowed, a doctor or an emergency department should be contacted immediately.

Q: Does the package insert for Oftan Akvakol mention any specific monitoring required?

Routine monitoring is typically not required for the general population using the topical solution. However, special medical oversight and potential dosage adjustments are noted for high-risk groups, such as newborn infants.

Advertisements

How should Oftan Akvakol be stored and disposed of?

How to Store and Dispose of Oftan Akvakol?

Oftan Akvakol (Chloramphenicol Eye Drops) must be stored according to strict regulatory requirements to maintain its stability and effectiveness.

Official Storage and Stability

Condition Requirement
Temperature (Unopened) Store refrigerated, between 2 C and 8 C.
Environmental Protection Protect the eye drops from light and do not freeze the solution.
Stability (After Opening) Discard the remaining contents 28 days after first opening the bottle.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Oftan Akvakol and any waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oftan Akvakol found in:

A-Z Index: